Recordati CEO sees ‘substantial opportunity’ in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company’s purchase of Sanofi’s rare immune disorder drug, Enjaymo.
Share
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company’s purchase of Sanofi’s rare immune disorder drug, Enjaymo.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email MNTN CEO Mark Douglas joins CNBC’s ‘The Exchange’ to discuss Disney as the company reported its fiscal fourth-quarter earnings, the performance of its streaming business, and more. Source link
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Eunice Yoon reports Chinese regulators have suspended market circuit breakers, according to the Shanghai Stock Exchange. 01:45 Thu, Jan 7 20169:43 AM EST Source link
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Brian Gardner, Stifel, joins ‘Fast Money’ to talk what Fed policy and economy will look like under president-elect Trump. 05:37 Thu, Nov 7 20246:06 PM EST Source link
Frederick Teo, GenZero CEO, says climate financing can’t be solved just by public finances. Source link
‘Mad Money’ host Jim Cramer breaks down how investors should position themselves for next week, what to expect from Walmart and Lowe’s earnings, and more. ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Source link
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Helima Croft discusses the potential impact of Chris Wright as Secretary of Energy, expecting less regulation and a rollback of Biden’s LNG pause. She highlights the role of shareholder demands in drilling decisions and suggests that stricter U.S. sanctions on Iran could…